TOP TEN perturbations for 1552456_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552456_a_at
Selected probe(set): 1552456_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552456_a_at (1552456_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):5.2077427
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

oncolytic herpes simplex virus study 4 / mock infected peripheral nerve sheath tumor (26T) cell sample

Relative Expression (log2-ratio):1.2084522
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 4
Human malignant peripheral nerve sheath tumor (26T) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (26T) cell sample
Human malignant peripheral nerve sheath tumor (26T) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / EWS/FLI-1 depletion study 3 (NT siRNA)

Relative Expression (log2-ratio):-0.9826107
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control EWS/FLI-1 depletion study 3 (NT siRNA)
Neuroepitheliomal SK-N-MC cells transfected with 1 nM non-targeting siRNA (NT siRNA) for 24 hours. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):0.975749
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / mock transfected SK-N-MC cell sample

Relative Expression (log2-ratio):-0.8234501
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control mock transfected SK-N-MC cell sample
Neuroepitheliomal SK-N-MC cells treated with transfection agent for 48 hours.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):0.8109627
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.800292
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.7592306
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):0.75495815
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):-0.75267315
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.

Organism: Homo sapiens
Gene: 1552456_a_at
Selected probe(set): 1552456_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552456_a_at (1552456_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):5.2077427
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

oncolytic herpes simplex virus study 4 / mock infected peripheral nerve sheath tumor (26T) cell sample

Relative Expression (log2-ratio):1.2084522
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 4
Human malignant peripheral nerve sheath tumor (26T) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (26T) cell sample
Human malignant peripheral nerve sheath tumor (26T) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / EWS/FLI-1 depletion study 3 (NT siRNA)

Relative Expression (log2-ratio):-0.9826107
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control EWS/FLI-1 depletion study 3 (NT siRNA)
Neuroepitheliomal SK-N-MC cells transfected with 1 nM non-targeting siRNA (NT siRNA) for 24 hours. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):0.975749
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / mock transfected SK-N-MC cell sample

Relative Expression (log2-ratio):-0.8234501
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control mock transfected SK-N-MC cell sample
Neuroepitheliomal SK-N-MC cells treated with transfection agent for 48 hours.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):0.8109627
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.800292
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.7592306
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):0.75495815
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):-0.75267315
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.

Organism: Homo sapiens
Gene: 1552456_a_at
Selected probe(set): 1552456_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552456_a_at (1552456_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):5.2077427
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

oncolytic herpes simplex virus study 4 / mock infected peripheral nerve sheath tumor (26T) cell sample

Relative Expression (log2-ratio):1.2084522
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 4
Human malignant peripheral nerve sheath tumor (26T) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (26T) cell sample
Human malignant peripheral nerve sheath tumor (26T) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / EWS/FLI-1 depletion study 3 (NT siRNA)

Relative Expression (log2-ratio):-0.9826107
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control EWS/FLI-1 depletion study 3 (NT siRNA)
Neuroepitheliomal SK-N-MC cells transfected with 1 nM non-targeting siRNA (NT siRNA) for 24 hours. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):0.975749
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / mock transfected SK-N-MC cell sample

Relative Expression (log2-ratio):-0.8234501
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control mock transfected SK-N-MC cell sample
Neuroepitheliomal SK-N-MC cells treated with transfection agent for 48 hours.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):0.8109627
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.800292
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.7592306
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):0.75495815
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):-0.75267315
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.

Organism: Homo sapiens
Gene: 1552456_a_at
Selected probe(set): 1552456_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552456_a_at (1552456_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):5.2077427
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

oncolytic herpes simplex virus study 4 / mock infected peripheral nerve sheath tumor (26T) cell sample

Relative Expression (log2-ratio):1.2084522
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 4
Human malignant peripheral nerve sheath tumor (26T) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (26T) cell sample
Human malignant peripheral nerve sheath tumor (26T) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / EWS/FLI-1 depletion study 3 (NT siRNA)

Relative Expression (log2-ratio):-0.9826107
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control EWS/FLI-1 depletion study 3 (NT siRNA)
Neuroepitheliomal SK-N-MC cells transfected with 1 nM non-targeting siRNA (NT siRNA) for 24 hours. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):0.975749
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / mock transfected SK-N-MC cell sample

Relative Expression (log2-ratio):-0.8234501
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control mock transfected SK-N-MC cell sample
Neuroepitheliomal SK-N-MC cells treated with transfection agent for 48 hours.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):0.8109627
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.800292
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.7592306
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):0.75495815
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):-0.75267315
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.

Organism: Homo sapiens
Gene: 1552456_a_at
Selected probe(set): 1552456_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552456_a_at (1552456_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

TC-71 / TC-32

Relative Expression (log2-ratio):5.2077427
Number of Samples:6 / 6
Experimental TC-71
Human primary cancer cell line derived from the humerus of a patient with Ewing sarcoma. Synonyms:TC71; GM11654 Cellosaurus code:
Control TC-32
Human primary cancer cell line derived from the unspecified origin of a patient with Ewing’s sarcoma. Synonyms:TC32 Cellosaurus code:

oncolytic herpes simplex virus study 4 / mock infected peripheral nerve sheath tumor (26T) cell sample

Relative Expression (log2-ratio):1.2084522
Number of Samples:2 / 2
Experimental oncolytic herpes simplex virus study 4
Human malignant peripheral nerve sheath tumor (26T) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (26T) cell sample
Human malignant peripheral nerve sheath tumor (26T) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / EWS/FLI-1 depletion study 3 (NT siRNA)

Relative Expression (log2-ratio):-0.9826107
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control EWS/FLI-1 depletion study 3 (NT siRNA)
Neuroepitheliomal SK-N-MC cells transfected with 1 nM non-targeting siRNA (NT siRNA) for 24 hours. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):0.975749
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

EWS/FLI-1 depletion study 3 (FLI-1 siRNA) / mock transfected SK-N-MC cell sample

Relative Expression (log2-ratio):-0.8234501
Number of Samples:4 / 2
Experimental EWS/FLI-1 depletion study 3 (FLI-1 siRNA)
Neuroepitheliomal SK-N-MC cell tranfected with 10nM FLI-1 siRNA to knock down the EWS/FLI-1 fusion within the transfected cell line. Another identical transfection was done 24 hours later and samples were taken 48 hours after the first transfection.
Control mock transfected SK-N-MC cell sample
Neuroepitheliomal SK-N-MC cells treated with transfection agent for 48 hours.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):0.8109627
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.800292
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.7592306
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):0.75495815
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):-0.75267315
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.